H. Kikuchi, H. Shimada, R. Karasawa
May 1, 2018
Citations
0
Influential Citations
0
Citations
Quality indicators
Journal
Nephrology Dialysis Transplantation
Abstract
INTRODUCTION AND AIMS: Lubiprostone (Lu) is a ClC-2 chloride channel activator approved for the treatment of chronic constipation. The channels are located on the apical aspect of intestinal epithelial cells. This drug has been reported to have serum phosphate (P) lowering effect in hemodialysis (HD) patients. The estimated mechanism of Lu action is to reduce P absorption by suppressing inflow or promoting excretion in the intestine. The aim of this study is to make a quantitative evaluation of Lu on P lowering effect in HD patients. We evaluated the change of daily P absorption by Lu administration and compared with that by ferric citrate (FC), lunthan carbonate (LC) and sucroferric oxyhydroxide (SO) administration.